spesolimab 
GtoPdb Ligand ID: 12169
|
Synonyms: BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
spesolimab is an approved drug (FDA and EMA (2022))
Compound class:
Antibody
Comment: Spesolimab (BI-655130) is a monoclonal antibody that disrupts interleukin-36 (IL-36)/IL-36 receptor signalling. Blocking this pathway is a molecular mechanism with potential to treat inflammatory diseases in skin and other epithelial tissues [2-3,5,7], since IL-36R expression is restricted to epithelial cells that are in direct contact with the environment, including those in the skin. Spesolimab (BI-655130) appears to be related to MAB92 which was reported by Boehringer Ingelheim in 2017 [6], but we have been unable to perform direct sequence matches. The heavy and light chain sequences for spesolimab (from its INN record) are claimed in Boehringer Ingelheim's patent US9023995B2 [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License